Search Videos by Topic or Participant
Browse by Series:

First-Line Dasatinib in Chronic Myeloid Leukemia

Panelists: Jessica K. Altman, MD, Northwestern University; Stuart L. Goldberg, MD, Rutgers;Elias Jabbour, MD, MD Anderson; Neil P. Shah, MD, PhD; UC
Published: Saturday, Feb 21, 2015
For High-Definition, Click
In the randomized DASISION trial, first-line imatinib was compared with dasatinib 100 mg once daily in patients with early chronic phase chronic myeloid leukemia (CML). Dasatinib demonstrated superiority based on the analyses of the primary endpoint of confirmed complete cytogenetic response (CCyR) within 12 months, and relevant secondary endpoints, Elias Jabbour, MD, describes.

Four-year follow-up data from DASISION showed that the superiority was maintained throughout the study period with deeper and faster responses. The major molecular response with dasatinib was 76% compared with 63% with imatinib. An optimal molecular response at 3 months was 84% with dasatinib versus 64% with imatinib. 
 
Once a patient achieves a deep response, the dose can be aggressively reduced, Neil Pravin Shah, MD, states. Additionally, brief drug interruptions can be utilized if side effects are troubling.
Slider Left
Slider Right
For High-Definition, Click
In the randomized DASISION trial, first-line imatinib was compared with dasatinib 100 mg once daily in patients with early chronic phase chronic myeloid leukemia (CML). Dasatinib demonstrated superiority based on the analyses of the primary endpoint of confirmed complete cytogenetic response (CCyR) within 12 months, and relevant secondary endpoints, Elias Jabbour, MD, describes.

Four-year follow-up data from DASISION showed that the superiority was maintained throughout the study period with deeper and faster responses. The major molecular response with dasatinib was 76% compared with 63% with imatinib. An optimal molecular response at 3 months was 84% with dasatinib versus 64% with imatinib. 
 
Once a patient achieves a deep response, the dose can be aggressively reduced, Neil Pravin Shah, MD, states. Additionally, brief drug interruptions can be utilized if side effects are troubling.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x